These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26398165)

  • 1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.
    Uppugunduri CR; George M
    J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165
    [No Abstract]   [Full Text] [Related]  

  • 2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 5. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
    [No Abstract]   [Full Text] [Related]  

  • 6. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
    Lettino M
    G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
    Ascaso JF
    Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
    [No Abstract]   [Full Text] [Related]  

  • 10. PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
    EBioMedicine
    EBioMedicine; 2015 Dec; 2(12):1835. PubMed ID: 26844247
    [No Abstract]   [Full Text] [Related]  

  • 11. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibitors are go.
    Mullard A
    Nat Rev Drug Discov; 2015 Sep; 14(9):593. PubMed ID: 26323538
    [No Abstract]   [Full Text] [Related]  

  • 13. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
    Norata GD; Tibolla G; Catapano AL
    Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) New Opportunities of Lipid-Lowering Therapy].
    Astrakova KS; Ragino YI; Shakhtshneider EV; Voevoda MI
    Kardiologiia; 2016 Sep; 56(9):84-91. PubMed ID: 28290871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Cornell JE; Mulrow CD
    Ann Intern Med; 2015 Aug; 163(3):242-3. PubMed ID: 26237759
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Battaggia A; Donzelli A; Font M
    Ann Intern Med; 2015 Aug; 163(3):241-2. PubMed ID: 26237758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.